Reuters logo
7 months ago
BRIEF-Anavex Life Sciences announces 12-month data of ANAVEX 2-73 in a phase 2a study in mild-to-moderate Alzheimer's disease patients
December 8, 2016 / 12:14 PM / 7 months ago

BRIEF-Anavex Life Sciences announces 12-month data of ANAVEX 2-73 in a phase 2a study in mild-to-moderate Alzheimer's disease patients

1 Min Read

Dec 8 (Reuters) - Anavex Life Sciences Corp

* Anavex Life Sciences announces 12-month data of ANAVEX 2-73 in a phase 2a study in mild-to-moderate Alzheimer's disease patients

* Phase 2a study for ANAVEX 2-73 met both primary and secondary endpoints

* At 57 weeks, Alzheimer's patients taking a daily oral dose between 10mg and 50mg, ANAVEX 2-73 was well tolerated

* In study, there were no clinically significant treatment-related adverse events and no serious adverse events Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below